Back to results
US 9,804,172 B2Granted
Soluble ST2 as a marker for risk of mortality in HIV-infected subjects
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paris Est Creteil Val De Marne, Assistance Publique-Hopitaux de Paris
InventorsYves Levy, Sophie Hue, Jean-Daniel Lelievre
Life of this patent
Estimating the term…
Abstract
The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.
Claims6
A method of predicting a risk of mortality within one year following a cardiovascular event, of an HIV-infected subject, and, based on the risk of mortality, treating the HIV-infected subject using a suitable method, comprising
- (i) measuring, in an HIV-infected subject who has no pre-existing cardiovascular disease and who has not yet commenced anti-HIV therapy, a level of sST2 in a biological sample from said subject,
- (ii) comparing said level of sST2 with a control level derived from HIV-infected subjects with no pre-existing cardiovascular disease, wherein a level of sST2 in the subject sample which is higher than that of the control is indicative of an increased risk of mortality;
- and
- (iii) treating the HIV-infected subject with an aggressive cardiovascular disease treatment when an elevated level of sST2 is detected in the subject sample compared to the control and treating the HIV-infected subject with a conservative cardiovascular disease treatment when the level of sST2 detected in the subject sample is not elevated compared to the control.
1 more element
Dependencies are inferred from the claim text.